Business Wire

REPLY

22.11.2021 09:32:03 CET | Business Wire | Press release

Share
REPLY: Reply’s Hybrid Work Research Confirms that “Hybrid work is not a passing trend”, as it Focuses on the Rapid Evolution of Technologies Designed to Support the New Ways of Working

Increased productivity and advanced collaboration are only two of the benefits the new hybrid work models bring and will soon be the new normal in the business world. This is precisely the outcome from the new Hybrid Work research carried with Reply’s Trend SONAR, the proprietary trend detection and monitoring platform based on Artificial Intelligence - with the support of PAC (Teknowlogy Group).

The research estimated the main market trends using sector studies and evidence collected from Reply customers. Data from two different clusters of countries were then compared: the “Europe-5” (Italy, Germany, France, the Netherlands, Belgium) and the “Big-5” (USA, United Kingdom, Brazil, China, India). The aim was to understand the maturity of the market after the spent year and a half of pandemic life.

Companies that have accelerated their digital transformation during the pandemic define the hybrid work model as popular, effective and performing –the very reasons why there will be no turning back.

Aside from a few limitations related to remote collaboration, which technological innovation will increasingly be able to minimise, the new normal does not provide for a full-time return to physical workplaces as before, but rather for greater flexibility and hybrid work paradigms. This approach is expected to revolutionise office design, corporate culture and the overall employee experience. This scenario will benefit employees with better work-life balance and increase of work efficiency, as well as companies: smaller office spaces, flexible working hours, hiring of talent without the need for relocation.

As Filippo Rizzante, Reply CTO, mentions: “The digital world and technology have reshaped the future of the employee experience. Regardless of the specific working context, be it an office or a factory, hybrid work will increasingly be characterised by the support and collaboration of software or hardware based on artificial intelligence. This will be facilitated by greater data literacy and a propensity for digitisation which will not only be the prerogative of developers, but will instead play a key role for the entire workforce. The transition to remote and flexible working models will, to a certain extent, become a permanent fixture and the new corporate culture will have to welcome and embrace the digital dimension as an integral part of daily work routines, facilitating social connections and communication on site, as well as remotely. What’s more, themes such as sustainability and employee well-being will increasingly become an integral part of a company’s DNA.”

To enable the hybrid work scenario, information must be accessible in the cloud and seamless and instant collaboration must be made possible through the adoption of the right tools for each business and activity. At the infrastructure level, cloud computing is not just an option, it is becoming the standard that is driving hybrid architectures. Spending on public and private cloud technologies already represents more than half of the current global infrastructure spending and this is expected to reach two thirds by 2024.

This acceleration and migration is also fuelling investments in productivity tools that consist mostly of cloud-based and intelligent technologies. Reply’s study highlights that among the Europe-5 countries, this market is expected to reach €7.6 billion by 2025. The push towards cloud computing will also drive the market of the countries that make up the Big-5 cluster, which are expected to reach a market of €36 billion.

Another trend highlighted by Reply’s research is the growth of hyperautomation; another approach based on Artificial Intelligence which extends the use of automation to value-added activities. By 2025, nearly half of the largest global companies are expected to support workers with smart technologies designed to assist with complex interactions.

Cybersecurity is also one of the main enabling technologies for hybrid work, precisely because one of the greatest obstacles to this type of work is the potential vulnerability of corporate networks. For this very reason, security is one of the major investment areas in 2021 and it is not expected to be a short-lived trend. It is estimated that by 2025 the market for end-user device security, in other words security solutions for PCs, smartphones, tablets and other corporate devices, will grow by 45% among the Big-5 countries and by 34% among the Europe-5 countries.

A strong focus on sustainability accompanies the Hybrid Work model: Reply’s research shows that the workforce, and in particular the new generations, search for companies that operate with a solid purpose, that act in a responsible and sustainable manner from an environmental point of view and that have the courage to take a stand in social and cultural debates - with clear and measurable corporate ESG standards. The well-being of the workforce, mental health and quality of life are gaining more relevance in the hybrid work environment, alongside physical safety.

Hybrid work has become an essential factor in retaining talent and when facing the great resignation phenomenon, with almost half of under 35s who, according to global data, are considering quitting their jobs if forced to return to the office full time. As the business landscape continues to change, organisations need to improve their existing capabilities and provide access to distance learning platforms. It is estimated that the Big-5’s spending on online learning platforms will increase by 48% by 2025 , reaching €16 billion, while among the Europe-5s this value will reach €2 billion.

The full research can be downloaded here . This new research is part of the Reply Market Research series, which includes the research papers on “From Cloud to Edge” , “Industrial IoT: a reality check” e “Beyond Digital Marketing ”.

Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ReplyinUK/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye